Key result
Ponatinib increases aortic VWF and platelet adhesion ~5-fold vs sham, inducing LV wall motion abnormalities.
Answers are grounded in this paper and cite their sources.
Demonstrates ponatinib induces von Willebrand factor-mediated platelet adhesion and microvascular angiopathy in mice, indicating a reversible mechanism of cardiotoxicity.
The third-generation tyrosine kinase inhibitor (TKI) ponatinib has been associated with high rates of acute ischemic events. The pathophysiology responsible for these events is unknown. We hypothesized that ponatinib produces an endothelial angiopathy involving excessive endothelial-associated von Willebrand factor (VWF) and secondary platelet adhesion. In wild-type mice and ApoE−/− mice on a Western diet, ultrasound molecular imaging of the thoracic aorta for VWF A1-domain and glycoprotein-Ibα was performed to quantify endothelial-associated VWF and platelet adhesion. After treatment of wild-type mice for 7 days, aortic molecular signal for endothelial-associated VWF and platelet adhesion were five- to sixfold higher in ponatinib vs sham therapy (P < .001), whereas dasatinib had no effect. In ApoE−/− mice, aortic VWF and platelet signals were two- to fourfold higher for ponatinib-treated compared with sham-treated mice (P < .05) and were significantly higher than in treated wild-type mice (P < .05). Platelet and VWF signals in ponatinib-treated mice were significantly reduced by N-acetylcysteine and completely eliminated by recombinant ADAMTS13. Ponatinib produced segmental left ventricular wall motion abnormalities in 33% of wild-type and 45% of ApoE−/− mice and corresponding patchy perfusion defects, yet coronary arteries were normal on angiography. Instead, a global microvascular angiopathy was detected by immunohistochemistry and by intravital microscopy observation of platelet aggregates and nets associated with endothelial cells and leukocytes. Our findings reveal a new form of vascular toxicity for the TKI ponatinib that involves VWF-mediated platelet adhesion and a secondary microvascular angiopathy that produces ischemic wall motion abnormalities. These processes can be mitigated by interventions known to reduce VWF multimer size.
No takes yet. Share an insight, caveat, or question.
Latifi et al. (2019) studied Ponatinib-induced cardiovascular toxicity / thrombotic microangiopathy. Ponatinib vs. Sham therapy or dasatinib was evaluated on Aortic molecular signal for endothelial-associated VWF and platelet adhesion (5- to 6-fold higher in wild-type mice; 2- to 4-fold higher in ApoE−/− mice, p=<0.001). Ponatinib increased aortic VWF and platelet adhesion 5- to 6-fold vs sham in wild-type mice and caused LV wall motion abnormalities in 33%-45% of mice.
Synapse has enriched 10 related papers. Consider them for comparative context: